Amgen Expects FDA to Set Panel Review of Bone Drug
Published: Jun 10, 2009
Reuters -- Amgen Inc expects the U.S. Food and Drug Administration to call for an advisory panel of osteoporosis experts to review its marketing application for experimental bone drug denosumab.